Ferrrero, J., Williams, L., Stella, H., et al. (2016) First-in-Human, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study of Aducanumab (BIIB037) in Mild-to-Moderate Alzheimer’s Disease. Alzheimer’s & Dementia, 2, 169-176.
https://doi.org/10.1016/j.trci.2016.06.002

has been cited by the following article:

• TITLE: Advances in Early Prevention of Alzheimer’s Disease in the Aged

  AUTHORS: Liu Zhang, Yanlin Heng, Gaijing Wang

  KEYWORDS: Aged, Early Prevention, Alzheimer’s Disease

  JOURNAL NAME: Yangtze Medicine, Vol.4 No.1, September 17, 2019

  ABSTRACT: Alzheimer’s disease (AD) is a progressive neurodegenerative disease, is one of the leading causes of death in the aging population, and has become a serious public problem endangering the physical and mental health of the elderly. The disease not only affects the health of the elderly and the quality of life in their later years, but also brings heavy financial and emotional burden to the family and society. The specific mechanism of AD is still unclear, and the current treatments focus on improving mental function and slowing down memory loss. The early diagnosis of AD is difficult and there is no cure for it, so the early prevention is particularly important. This review will introduce the major treatment, potential risk factors and summarize the relevant research about early preventions of AD, such as regular physical sports, reasonable nutritional diet, certain social activities and so on, and expect to provide a new direction for the improvement of AD.